Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Generation of Autologous CMV and EBV-Specific T-Cell Lines from Seronegative Patients for Cell Therapy of Opportunistic Infections Following Kidney Transplantation.
C. Lamarche,¹ T. Pincez,¹ J. Orio,¹ C. Carli,¹ A. Humar,² J.-S. Delisle.¹
¹Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; ²Toronto General Research Institute, Toronto, ON, Canada
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations after kidney transplant are associated with substantial morbidity, especially in seronegative patients. Adoptive immunotherapy using virus-specific T cells…
2017 American Transplant Congress
Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant.
S. Pineda,^1,2 T. Sigdel,² A. Jackson,³ M. Sirota,^1,2 M. Sarwal.²
¹Institute for Computational Health Science, University of California, San Francisco (UCSF), San Francisco, CA; ²Department of Surgery, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), CA; ³Department of Medicine, Johns Hopkins, Baltimore, MD
Background: The objective of this work is to characterize the impact of the donor-recipient (D/R) HLA and non-HLA mismatches on the risk of antibody-mediated rejection…
2017 American Transplant Congress
Incidence of Fungal and Viral Infections Following Rituximab Use in Kidney Transplant Recipients.
L. Wong, M. Ison, C. Richardson, K. Cunningham, C. D'Agostino, C. Tseng, A. Shetty.
Northwestern Memorial Hospital, Chicago, IL
Rituximab is used off-label in solid organ transplant for desensitization and treatment of antibody-mediated rejection (AMR). It targets CD20 and results in B cell depletion.…
2017 American Transplant Congress
Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation.
B. Ho,¹ H. Bhagat,² E. Lee,^2,3 K. Atiemo,¹ A. Daud,¹ R. Kang,¹ S. Montag,^1,4 L. Zhao,^1,4 J. Schwartz,² D. Ladner.¹
¹Northwestern University Transplant and Outcomes Research Collaborative (NUTORC), Chicago; ²Astellas Pharma Global Development, Northbrook; ³Now with UCB, Atlanta; ⁴Dept of Preventive Medicine, Northwestern University, Chicago
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens (HLA) contributes to inferior kidney transplant (KT) outcomes. No data exist on healthcare resource…
2017 American Transplant Congress
Understanding the Role of Induction Agents in Older versus Younger Kidney Transplant Recipients.
Q. Huang, F. Ammary, M. McAdams-DeMarco, D. Segev.
Johns Hopkins University, Baltimore, MD
Background: There has been an increase in the number of older (over 65) KT recipients. Aging-related changes such as differences in immune senescence may influence…
2017 American Transplant Congress
Triptolide Alleviating Acute Antibody Mediated Rejection by Inhibition of B Cell Activation in Presensitized Recipients.
D. Zhao,¹ S. Li,¹ T. Liao,¹ Y. Wei,² X. Hua,¹ F. Han,¹ Z. Luo,¹ X. Liu,¹ Q. Sun.
¹Kidney Transplantation, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; ²Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China
Backgroud: Acute antibody mediated rejection (AMR), resistant to most anti-rejection therapy, is main cause for renal graft loss. Triptolide(TPL) had been reported as a promising…
2017 American Transplant Congress
Kidney Transplantation Outcomes from Donors with Acute Kidney Injury.
S. Channapatna Suresh, M. Lubetzky, J. Graham, A. Chokechanaisakul, O. Mohammed, M. Kinkhabwala, E. Akalin, J. Rocca, P. Bedi.
Abdominal Transplant Surgery, Montefiore Medical Center, Bronx, NY
Background- Organ scarcity and increased waiting times for kidney transplantation has led the transplant community to utilize more sub-optimal organs while continuing providing survival benefit…
2017 American Transplant Congress
Increasing Living Donation by Implementing the Kidney Coach Program.
D. LaPointe Rudow, S. Geatrakas, J. Armenti, A. Tomback, R. Shapiro.
Recanati Miller Transplantation Institute, Mount Sinai Hospital, New York, NY
Introduction: It is firmly established that for patients requiring transplant, living donor kidney transplantation (LDKT) is better than deceased donor transplantation. However, recipients find it…
2017 American Transplant Congress
Pregnancy Outcomes in Female Kidney Transplant Recipients Using Assisted Fertility Methods.
L. Coscia,¹ D. Armenti,¹ S. Constantinescu,^1,2 M. Moritz.^1,3,4
¹Transplant Pregnancy Registry, Gift of Life Institute, Philadelphia, PA; ²Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; ³Surgery, Lehigh Valley Health Network, Allentown, PA; ⁴Morsani College of Medicine, USF, Tampa, FL
The purpose of this study was to analyze pregnancy and transplant outcomes in female kidney recipients who used fertility medications alone (FM), intrauterine insemination (IUI),…
2017 American Transplant Congress
Impact of Type 2 Surgical Injuries in Postmortem Donor Kidneys on the Post-Transplant Outcomes When Compared to Mate Non-Injured Kidney from the Same Donor.
M. Mujtaba,¹ A. Gamilla-Crudo,¹ K. Gugliuzza,² O. Aleter,¹ S. Shah,¹ Y. Chapman,³ J. Reese,³ S. Masood,¹ T. Taber.⁴
¹Division of Nephrology and Hypertension, University of Texas Medical Branch, Galveston, TX; ²Department of Surgery, University of Texas Medical Branch, Galveston, TX; ³Southwest Transplant Alliance, Dallas, TX; ⁴Division of Nephrology, Indiana University, Indianapolis, IN
Introduction - While damage to the procured organ is rare with organ loss being approximately 0.3% of procured organs, loss of potential transplantable organs does…